The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-04 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Often the response is determined as a function of log[L] to consider many orders of magnitude of concentration. However, there is no biological or physical theory that relates effects to the log of concentration. It is just convenient for graphing purposes. It is useful to note that 50% of the receptors are bound when [L]=Kd . The graph shown represents the conc-response for two hypothetical receptor agonists, plotted in a semi-log fashion. The curve toward the left represents a higher potency (potency arrow does not indicate direction of increase) since lower concentrations are needed for a given response. The effect increases as a function of concentration.
=== Obesity === In 1984, researchers at the University of Rochester Medical Center reported that they had performed a double-blind, controlled clinical trial comparing phentermine alone, fenfluramine alone, a combination of phentermine and fenfluramine, and placebo, for weight loss in humans. Weight loss in those receiving the fen-phen combination was significantly greater (8.4±1.1 kg) than in those receiving placebo (4.4±0.9 kg) and equivalent to that of those receiving fenfluramine (7.5±1.2 kg) or phentermine alone (10.0±1.2 kg). This amounts to an additional weight loss of 4±2 kg over the course of 24 weeks. Adverse effects were less frequent with the combination regimen than with the other active (non-placebo) treatments. The authors felt that combining fenfluramine and phentermine capitalized on their pharmacodynamic differences, resulting in equivalent weight loss, fewer adverse effects, and better appetite control.
== Morphology == Blastocystis hominis demonstrates tremendous morphological plasticity throughout its life cycle. The vacuolar form, which is most usually seen in laboratory cultures, has a large central vacuole surrounded by peripheral cytoplasm containing the nucleus and other organelles. The granular form appears similar, but it has discrete granules within the central vacuole, which could represent metabolic products or reproductive elements. The amoeboid type has an irregular shape with pseudopod-like extensions and is commonly seen in symptomatic patients. Recent electron microscopy studies have shown sophisticated interior features, such as surface coat variations and organelles that resemble mitochondria.
Sources: en.wikipedia.org
Opioid withdrawal can occur with a sudden decrease in, or cessation of, opioids after prolonged use. Onset of withdrawal depends on the half-life of the opioid that was used last. With heroin this typically occurs five hours after use. With methadone, it may take two days. How long major symptoms last also depends on the opioid used. For heroin withdrawal, symptoms are typically greatest at two to four days and can last up to two weeks. Less significant symptoms may last longer, in which case the withdrawal is known as post-acute-withdrawal syndrome.
Select patients with salvageable tissue Another element of clinical trial design is the use of imaging biomarkers to select patients that are likely to benefit from therapy. MRI and CT imaging methods that determine whether a patient is likely to have salvageable tissue have been used to great effect in clinical trials that showed the benefit of mechanical thrombectomy devices. These same methods can be applied to clinical trials for cerebroprotective drugs. Restore blood flow after protection so that protected tissue can survive long term If a drug protects the brain from reduced blood flow but then wears off before blood flow is normalized, then the long term effect of the drug may not be as great as it would be if the drug were paired with therapy to normalize blood flow. Pairing cerebroprotective drugs with approved methods to restore blood flow, such as tPA or mechanical thrombectomy, may increase their long term benefit.
=== From lifestyle === Habitual snoring may be a risk factor for MASLD. Severe snoring often signals the presence of obstructive sleep apnea (OSA), a much more serious breathing condition. Blockage or narrowing of the airways, even temporarily, can cause the body to experience lowered oxygen levels in the blood. This, in turn, may cause a variety of changes within the body, such as tissue inflammation, increased insulin resistance, and liver injury. A prospective cohort study found the association between habitual snoring and MASLD development to be significant, and the trend was noted to be most prominent in lean individuals.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。